ALEXANDRIA, VA USA (Press Release) - February 23, 2015 -
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.
Summary includes updated data not in the abstract
A case-control study of close to 180,000 men suggests that the incidence of prostate cancer is higher among men with a history of testicular cancer (12.6 percent) than among those without a history of testicular cancer (2.8 percent). Men who have had testicular cancer were also more likely to develop intermediate- or high-risk prostate cancers. The study will be presented at the upcoming 2015 Genitourinary Cancers Symposium in Orlando.
“Men with a history of testicular cancer should talk with their doctor about assessing their risk for prostate cancer, given there may be an increased risk,” said senior study author Mohummad Minhaj Siddiqui, MD, an assistant professor of surgery at the University of Maryland School of Medicine and director of urologic robotic surgery at the University of Maryland Marlene and Stewart Greenebaum Cancer Center in Baltimore, Md. “It is too soon to make any practice recommendations based on this single study, but the findings provide groundwork for further research into the biologic link between the two diseases.”
Researchers analyzed Surveillance, Epidemiology, and End Results (SEER) data on 32,435 men with a history of testicular cancer and 147,044 men with a history of melanoma. Melanoma was used as the control group because there is no known association between melanoma and prostate cancer. It is expected that patients with melanoma would have a similar risk for developing prostate cancer as men in the general population. On average, men in both groups developed prostate cancer about 30 years after their first cancer was diagnosed.
The overall incidence of prostate cancer by age 80 was significantly higher among men with a history of testicular cancer compared to the control (12.6 vs. 2.8 percent). The incidence of intermediate- or high-risk prostate cancer was also increased in the testicular cancer group compared to the control group (5.8 percent vs. 1.1 percent). Testicular cancer was associated with a 4.7 times higher risk of developing all prostate cancers and 5.2 times higher risk of developing intermediate- or high-risk disease.
Dr. Siddiqui remarked that it is important to keep in mind that the chance of developing intermediate- or high-risk prostate cancer is low – 95 percent of men with a history of testicular cancer will not get it.
The American Society of Clinical Oncology (ASCO) is the world’s leading professional organization representing physicians who care for people with cancer. With more than 35,000 members, ASCO is committed to improving cancer care through scientific meetings, educational programs and peer-reviewed journals. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation, which funds ground-breaking research and programs that make a tangible difference in the lives of people with cancer. For ASCO information and resources, visit www.asco.org. Patient-oriented cancer information is available at www.Cancer.Net.
[ PRESS RELEASE ]